Score Fusion by Maximizing the Area under the ROC Curve

The final publication is available at Springer via http://dx.doi.org/10.1007/978-3-642-02172-5_61Information fusion is currently a very active research topic aimed at improving the performance of biometric systems. This paper proposes a novel method for optimizing the parameters of a score fusion model based on maximizing an index related to the Area Under the ROC Curve. This approach has the convenience that the fusion parameters are learned without having to specify the client and impostor priors or the costs for the different errors. Empirical results on several datasets show the effectiveness of the proposed approach.Work supported by the Spanish projects DPI2006-15542-C04 and TIN2008-04571 and the Generalitat Valenciana - Consellería d’Educació under an FPI scholarship.Villegas Santamaría, M.; Paredes Palacios, R. (2009). Score Fusion by Maximizing the Area under the ROC Curve. En Pattern Recognition and Image Analysis: 4th Iberian Conference, IbPRIA 2009 Póvoa de Varzim, Portugal, June 10-12, 2009 Proceedings. Springer Verlag (Germany). 473-480. https://doi.org/10.1007/978-3-642-02172-5_61S473480Toh, K.A., Kim, J., Lee, S.: Biometric scores fusion based on total error rate minimization. Pattern Recognition 41(3), 1066–1082 (2008)Jain, A., Nandakumar, K., Ross, A.: Score normalization in multimodal biometric systems. Pattern Recognition 38(12), 2270–2285 (2005)Gutschoven, B., Verlinde, P.: Multi-modal identity verification using support vector machines (svm). In: Proceedings of the Third International Conference on Information Fusion. FUSION 2000, vol. 2, pp. THB3/3–THB3/8 (July 2000)Ma, Y., Cukic, B., Singh, H.: A classification approach to multi-biometric score fusion. In: Kanade, T., Jain, A., Ratha, N.K. (eds.) AVBPA 2005. LNCS, vol. 3546, pp. 484–493. Springer, Heidelberg (2005)Maurer, D.E., Baker, J.P.: Fusing multimodal biometrics with quality estimates via a bayesian belief network. Pattern Recogn. 41(3), 821–832 (2008)Ling, C.X., Huang, J., Zhang, H.: Auc: a statistically consistent and more discriminating measure than accuracy. In: Proc. of IJCAI 2003, pp. 519–524 (2003)Yan, L., Dodier, R.H., Mozer, M., Wolniewicz, R.H.: Optimizing classifier performance via an approximation to the wilcoxon-mann-whitney statistic. In: Machine Learning, Proceedings of the Twentieth International Conference (ICML 2003), Washington, DC, USA, pp. 848–855. AAAI Press, Menlo Park (2003)Marrocco, C., Molinara, M., Tortorella, F.: Exploiting auc for optimal linear combinations of dichotomizers. Pattern Recogn. Lett. 27(8), 900–907 (2006)Marrocco, C., Duin, R.P.W., Tortorella, F.: Maximizing the area under the roc curve by pairwise feature combination. Pattern Recogn. 41(6), 1961–1974 (2008)Paredes, R., Vidal, E.: Learning prototypes and distances: a prototype reduction technique based on nearest neighbor error minimization. Pattern Recognition 39(2), 180–188 (2006)Villegas, M., Paredes, R.: Simultaneous learning of a discriminative projection and prototypes for nearest-neighbor classification. In: IEEE Conference on Computer Vision and Pattern Recognition. CVPR 2008, pp. 1–8 (2008)Nandakumar, K., Chen, Y., Dass, S.C., Jain, A.: Likelihood ratio-based biometric score fusion. IEEE Transactions on Pattern Analysis and Machine Intelligence 30(2), 342–347 (2008)Poh, N., Bengio, S.: A score-level fusion benchmark database for biometric authentication. In: Kanade, T., Jain, A., Ratha, N.K. (eds.) AVBPA 2005. LNCS, vol. 3546, pp. 1059–1070. Springer, Heidelberg (2005)National Institute of Standards and Technology: NIST Biometric Scores Set - Release 1 (BSSR1) (2004), http://www.itl.nist.gov/iad/894.03/biometricscores/Bengio, S., Mariéthoz, J., Keller, M.: The expected performance curve. In: Proceedings of the Second Workshop on ROC Analysis in ML, pp. 9–16 (2005

Silicon carbide particulates incorporated into microalloyed steel surface using TIG: microstructure and properties

Surface metal matrix composites have been developed to enhance properties such as erosion, wear and corrosion of alloys. In this study, ~5 µm or ~75 µm SiC particulates were preplaced on a microalloyed steel. Single track surface zones were melted by a tungsten inert gas torch, and the effect of two heat inputs, 420Jmm-1 and 840 Jmm-1,compared. The results showed that the samples melted using 420Jmm-1 were crack-free. Pin-on-disk wear testing under dry sliding conditions were conducted. The effects of load and sliding velocity were used to characterise the performance of the crack-free samples. Microstructural and X-ray diffraction studies of the surface showed that the SiC had dissolved, and that martensite, was the main phase influencing the hardness

The Arabidopsis thaliana F-Box Protein FBL17 Is Essential for Progression through the Second Mitosis during Pollen Development

In fungi and metazoans, the SCF-type Ubiquitin protein ligases (E3s) play a critical role in cell cycle regulation by degrading negative regulators, such as cell cycle-dependent kinase inhibitors (CKIs) at the G1-to-S-phase checkpoint. Here we report that FBL17, an Arabidopsis thaliana F-box protein, is involved in cell cycle regulation during male gametogenesis. FBL17 expression is strongly enhanced in plants co-expressing E2Fa and DPa, transcription factors that promote S-phase entry. FBL17 loss-of-function mutants fail to undergo pollen mitosis II, which generates the two sperm cells in mature A. thaliana pollen. Nonetheless, the single sperm cell-like cell in fbl17 mutants is functional but will exclusively fertilize the egg cell of the female gametophyte, giving rise to an embryo that will later abort, most likely due to the lack of functional endosperm. Seed abortion can, however, be overcome by mutations in FIE, a component of the Polycomb group complex, overall resembling loss-of-function mutations in the A. thaliana cyclin-dependent kinase CDKA;1. Finally we identified ASK11, as an SKP1-like partner protein of FBL17 and discuss a possible mechanism how SCFFBL17 may regulate cell division during male gametogenesis

MicroRNA-Restricted Transgene Expression in the Retina

Background: Gene transfer using adeno-associated viral (AAV) vectors has been successfully applied in the retina for the treatment of inherited retinal dystrophies. Recently, microRNAs have been exploited to fine-tune transgene expression improving therapeutic outcomes. Here we evaluated the ability of retinal-expressed microRNAs to restrict AAV-mediated transgene expression to specific retinal cell types that represent the main targets of common inherited blinding conditions. Methodology/Principal Findings: To this end, we generated AAV2/5 vectors expressing EGFP and containing four tandem copies of miR-124 or miR-204 complementary sequences in the 39UTR of the transgene expression cassette. These vectors were administered subretinally to adult C57BL/6 mice and Large White pigs. Our results demonstrate that miR-124 and miR-204 target sequences can efficiently restrict AAV2/5-mediated transgene expression to retinal pigment epithelium and photoreceptors, respectively, in mice and pigs. Interestingly, transgene restriction was observed at low vector doses relevant to therapy. Conclusions: We conclude that microRNA-mediated regulation of transgene expression can be applied in the retina to either restrict to a specific cell type the robust expression obtained using ubiquitous promoters or to provide an additiona

Epigenetic regulation of prostate cancer

Prostate cancer is a commonly diagnosed cancer in men and a leading cause of cancer deaths. Whilst the underlying mechanisms leading to prostate cancer are still to be determined, it is evident that both genetic and epigenetic changes contribute to the development and progression of this disease. Epigenetic changes involving DNA hypo- and hypermethylation, altered histone modifications and more recently changes in microRNA expression have been detected at a range of genes associated with prostate cancer. Furthermore, there is evidence that particular epigenetic changes are associated with different stages of the disease. Whilst early detection can lead to effective treatment, and androgen deprivation therapy has a high response rate, many tumours develop towards hormone-refractory prostate cancer, for which there is no successful treatment. Reliable markers for early detection and more effective treatment strategies are, therefore, needed. Consequently, there is a considerable interest in the potential of epigenetic changes as markers or targets for therapy in prostate cancer. Epigenetic modifiers that demethylate DNA and inhibit histone deacetylases have recently been explored to reactivate silenced gene expression in cancer. However, further understanding of the mechanisms and the effects of chromatin modulation in prostate cancer are required. In this review, we examine the current literature on epigenetic changes associated with prostate cancer and discuss the potential use of epigenetic modifiers for treatment of this disease

The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry

Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in Europe. Data from real-world registries are necessary, as clinical trials do not represent the full spectrum of VTE patients seen in clinical practice. We aimed to document the epidemiology, management and outcomes of VTE using data from a large, observational database. PREFER in VTE was an international, non-interventional disease registry conducted between January 2013 and July 2015 in primary and secondary care across seven European countries. Consecutive patients with acute VTE were documented and followed up over 12 months. PREFER in VTE included 3,455 patients with a mean age of 60.8 ± 17.0 years. Overall, 53.0 % were male. The majority of patients were assessed in the hospital setting as inpatients or outpatients (78.5 %). The diagnosis was deep-vein thrombosis (DVT) in 59.5 % and pulmonary embolism (PE) in 40.5 %. The most common comorbidities were the various types of cardiovascular disease (excluding hypertension; 45.5 %), hypertension (42.3 %) and dyslipidaemia (21.1 %). Following the index VTE, a large proportion of patients received initial therapy with heparin (73.2 %), almost half received a vitamin K antagonist (48.7 %) and nearly a quarter received a DOAC (24.5 %). Almost a quarter of all presentations were for recurrent VTE, with >80 % of previous episodes having occurred more than 12 months prior to baseline. In conclusion, PREFER in VTE has provided contemporary insights into VTE patients and their real-world management, including their baseline characteristics, risk factors, disease history, symptoms and signs, initial therapy and outcomes

Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes

Background: Albuminuria has been classically considered a marker of kidney damage progression in diabetic patients and it is routinely assessed to monitor kidney function. However, the role of a mild GFR reduction on the development of stage 653 CKD has been less explored in type 1 diabetes mellitus (T1DM) patients. Aim of the present study was to evaluate the prognostic role of kidney disease measures, namely albuminuria and reduced GFR, on the development of stage 653 CKD in a large cohort of patients affected by T1DM. Methods: A total of 4284 patients affected by T1DM followed-up at 76 diabetes centers participating to the Italian Association of Clinical Diabetologists (Associazione Medici Diabetologi, AMD) initiative constitutes the study population. Urinary albumin excretion (ACR) and estimated GFR (eGFR) were retrieved and analyzed. The incidence of stage 653 CKD (eGFR < 60 mL/min/1.73 m2) or eGFR reduction > 30% from baseline was evaluated. Results: The mean estimated GFR was 98 \ub1 17 mL/min/1.73m2 and the proportion of patients with albuminuria was 15.3% (n = 654) at baseline. About 8% (n = 337) of patients developed one of the two renal endpoints during the 4-year follow-up period. Age, albuminuria (micro or macro) and baseline eGFR < 90 ml/min/m2 were independent risk factors for stage 653 CKD and renal function worsening. When compared to patients with eGFR > 90 ml/min/1.73m2 and normoalbuminuria, those with albuminuria at baseline had a 1.69 greater risk of reaching stage 3 CKD, while patients with mild eGFR reduction (i.e. eGFR between 90 and 60 mL/min/1.73 m2) show a 3.81 greater risk that rose to 8.24 for those patients with albuminuria and mild eGFR reduction at baseline. Conclusions: Albuminuria and eGFR reduction represent independent risk factors for incident stage 653 CKD in T1DM patients. The simultaneous occurrence of reduced eGFR and albuminuria have a synergistic effect on renal function worsening